MedTrace Logo

A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients

NCT00926562 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 592

Last updated 2011-06-27

No results posted yet for this study

Summary

The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Iopromide (Ultravist)

Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM

DRUG

Iodixanol (Visipaque)

Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Yundai Chen, MD · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-12-31
Completion
2011-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926562 on ClinicalTrials.gov